secwatch.observer — SEC 8-K summary
======================================

Issuer:     VYCOR MEDICAL INC (VYCO)
CIK:        0001424768
Form:       8-K
Filed at:   2025-05-15T23:59:59+00:00
Accession:  0001641172-25-010594
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vycor Medical Q1 revenue up 30% to $436k; operating profit turns positive
-------------------------------------------------------------------------

- Revenue of $436,378 (+30% YoY); Vycor Medical division revenue $418,520 (+31%).
- Non-GAAP cash operating profit of $21,619 vs $8,452 in prior year.
- Gross margin 82% (down from 89%) due to validation, shipping costs and sales mix.
- New distribution agreements signed for France and Spain; three VBAS clinical papers published.
- NovaVision division revenue $17,858 (-3% YoY), remains in development stage.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/0001641172-25-010594-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1424768/000164117225010594/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-010594

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer